PTC Therapeutics

PTCT · Nasdaq · United States

Share price · PTCT

$60.23-12.40 (-17.07%) 3M

close as of 2026-11-18 · 24h delayed · vol 643K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PTCT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+11.9%
  2. 30 Oct 2026-7.0%
  3. 28 Sep 2026+5.2%
  4. 31 Jul 2026-9.9%
  5. 8 May 2026+14.3%
  6. 29 Apr 2026-8.1%
  7. 9 Mar 2026+8.9%
  8. 16 Jan 2026-4.2%

    Nothing announced by PTCT that day or the session before.

  9. 1 Dec 2025-7.9%

Share of unusual movement by asset

For each asset, the share of PTCT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Sepiapterin
events and moves
5shown from 8 days
isaralgagene civaparvovec
events and moves
2shown from 8 days
Vatiquinone (PTC743)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—43%
Sessions with no dated event—52%

Assets

(5 total)
5Total Assets
2Approved
2Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
AADC (aromatic L-amino acid decarboxylase)Gene therapy / editing
AADC Deficiency
Approved
Phenylalanine hydroxylase (PAH)Small molecule
Phenylketonuria
Phase 3
15-lipoxygenase (15-LO)Small molecule
Friedreich Ataxia
Volanesorsen(Waylivra)No recent activity
Phase 3
APOC3 mRNARNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere Hypertriglyceridemia
Phase 1/2
Alpha-galactosidase A (GLA / α-Gal A)Gene therapy / editing
Fabry Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Vatiquinone (PTC743)Phase 3Friedreich Ataxia
Est. primary completion 2027-12-31 · NCT05515536 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Vatiquinone (PTC743)Phase 3Friedreich's Ataxia
Est. primary completion 2029-03-15 · NCT07681713 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
SepiapterinPhase 3Phenylketonuria
Est. primary completion 2031-02-28 · NCT06302348 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 December 2025ApprovalSepiapterinSephience approved in Japan for PKU
JP, MHLW · Source ↗
19 August 2025Complete response letterVatiquinone (PTC743)FDA issues complete response letter for the vatiquinone NDA in Friedreich's ataxia
US, FDA · PTC Therapeutics · Source ↗
February 2025Filing acceptedVatiquinone (PTC743)FDA accepts the vatiquinone NDA
US, FDA · Source ↗
December 2024Filing submittedVatiquinone (PTC743)Vatiquinone NDA submitted to the FDA
US, FDA · Source ↗
October 2024Topline resultVatiquinone (PTC743)Long-term extension studies met their prespecified endpoint

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$358M$105M$525M+ $1.6B short-term inv.$52M-$25M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$361M$99M$1.1B+ $1.2B short-term inv.—$129M operating cash flowreport ↗
2026-Q1$273M$101M$850M+ $1.1B short-term inv.$2.8M-$59M operating cash flowreport ↗
2025-Q3$211M$100M$686M+ $1.0B short-term inv.—-$66M operating cash flowreport ↗
2025-Q2$179M$113M$1.0B+ $972M short-term inv.$65M-$58M operating cash flowreport ↗
2025-Q1$1.2B$109M$1.5B+ $547M short-term inv.—$870M operating cash flowreport ↗
2024-Q3$197M$161M$540M+ $487M short-term inv.$107M-$77M operating cash flowreport ↗
2024-Q2$187M$132M$669M+ $439M short-term inv.$99M-$71M operating cash flowreport ↗
2024-Q1$210M$116M$565M+ $336M short-term inv.$92M$71M operating cash flowreport ↗
2023-Q3$197M$164M$181M+ $130M short-term inv.$133M-$15M operating cash flowreport ↗
2023-Q2$214M$186M$225M+ $130M short-term inv.$199M-$14M operating cash flowreport ↗
2023-Q1$220M$195M$234M+ $119M short-term inv.$139M-$29M operating cash flowreport ↗
2022-Q3$217M$165M$121M+ $184M short-term inv.$109M-$38M operating cash flowreport ↗
2022-Q2$166M$157M$174M+ $347M short-term inv.$152M-$55M operating cash flowreport ↗
2022-Q1$149M$140M$152M+ $444M short-term inv.$127M-$97M operating cash flowreport ↗
2021-Q3$139M$131M$197M+ $678M short-term inv.$134M-$51M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.7B$455M$998M+ $961M short-term inv.—$711M operating cash flowreport ↗

PTC Therapeutics reported full-year 2025 revenue of $1,730.66M, up 114.5% YoY, with collaboration and license revenue of $998.4M from the votoplam agreement with Novartis contributing substantially. R&D spend was $455.25M, down 14.8% YoY, and the company ended the year with cash and equivalents of $998.33M. Net income was $682.64M for 2025, a swing from the prior-year net loss.

For 2026, PTC guides total product revenue of $700–800 million, a 19–36% increase from 2025, with the majority from Sephience, plus GAAP R&D and SG&A expense of $775–815 million (non-GAAP $680–720 million). Sephience generated $111M in 2025 since its launch, received approvals in Japan and Brazil, and is expected to expand to 20–30 countries by end of 2026. The company also reported FDA alignment on a planned Phase 3 trial (INVEST-HD) for votoplam in Huntington’s disease, with initiation expected in 1H 2026, and noted the FDA indicated an additional study, potentially open-label with a natural history control, is needed for vatiquinone in Friedreich’s ataxia. In December 2025, PTC sold the remainder of its Evrysdi royalty to Royalty Pharma for $240M upfront and up to $60M in milestones.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$807M$534M$795M+ $360M short-term inv.$91M-$108M operating cash flowreport ↗
2023-FY$938M$667M$610M+ $283M short-term inv.$157M-$158M operating cash flowreport ↗
2022-FY$699M$652M$296M+ $131M short-term inv.$140M-$357M operating cash flowreport ↗
2021-FY$539M$541M$197M+ $584M short-term inv.$131M-$251M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 203 sales ($56.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Boulding Mark Elliott · EXEC. VP AND CLOOption exercise2,812$25.69$72KForm 4
2026-11-16Boulding Mark Elliott · EXEC. VP AND CLOOpen-market sale1,315$61.39$81KForm 4
2026-11-16Boulding Mark Elliott · EXEC. VP AND CLOOpen-market sale1,288$62.22$80KForm 4
2026-11-16Boulding Mark Elliott · EXEC. VP AND CLOOpen-market sale209$62.90$13KForm 4
2026-11-16Boulding Mark Elliott · EXEC. VP AND CLOOption exercise (derivative)2,812——Form 4
2026-10-14SCHMERTZLER MICHAEL · directorOpen-market sale2,118$59.52$126KForm 4
2026-10-14SCHMERTZLER MICHAEL · directorOpen-market sale382$60.14$23KForm 4
2026-10-09Boulding Mark Elliott · EXEC. VP AND CLOOption exercise192$39.42$8KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 348 reporting institutions held 95.5M shares ($6.4B, 114.3% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.12,948,717$882.2M
2RTW INVESTMENTS, LP7,746,415$527.8M
3JANUS HENDERSON GROUP PLC7,193,433$490.0M
4VANGUARD PORTFOLIO MANAGEMENT LLC4,804,594$327.3M
5STATE STREET CORP4,346,519$296.1M
6WELLINGTON MANAGEMENT GROUP LLP3,942,610$268.6M
7VANGUARD CAPITAL MANAGEMENT LLC3,676,256$250.5M
8TORONTO DOMINION BANK3,025,963$206.2M
9GEODE CAPITAL MANAGEMENT, LLC2,209,954$150.6M
10ARMISTICE CAPITAL, LLC2,074,449$141.3M
11BANK OF AMERICA CORP /DE/1,886,841$128.6M
12Hood River Capital Management LLC1,664,559$113.4M
13D. E. Shaw & Co., Inc.1,640,381$111.8M
14FMR LLC1,528,362$104.1M
15TANG CAPITAL MANAGEMENT LLC1,500,000$102.2M